ALIS-FLP: amplified ligation selected fragment-length polymorphism method for microbial genotyping.
A DNA fingerprinting method known as ALIS-FLP (amplified ligation selected fragment-length polymorphism) has been developed for selective and specific amplification of restriction fragments from TspRI restriction endonuclease digested genomic DNA. The method is similar to AFLP, but differs in that only one specific restriction enzyme (TspRI) is used. The cohesive ends of the DNA fragments are ligated with two types of oligonucleotide. A long oligonucleotide containing the primer site and the specific 9 nt 3 prime end, which is complementary to specific 9 nt, cohesive 3 prime end of the TspRI genomic DNA fragment, and a short, degenerated, oligonucleotide covering the remaining TspRI cohesive ends. Other cohesive ends are covered by a short degenerated oligonucleotide lacking the primer site. The ligation mixture is used as a template for amplification using a single primer corresponding to the 5 prime end of the long, specific oligonucleotide. The selection of TspRI digested genomic DNA fragments for amplification is achieved by sequence selective ligation of the specific long oligonucleotide carrying the primer site to both ends of the specific target fragment. This technique allows for differentiation of the organisms without previous knowledge of their DNA sequence. The usefulness of the method is confirmed by genotyping of 70 previously characterized clinical E. coli isolates. The grouping obtained was identical to the results of REA-PFGE. Versatility of the method is highlighted, i.e. its combining the advantages of the AFLP technique with a simple, rapid and cheap polymerase chain reaction product detection method.
Brillowska-Dabrowska
Anna
A
Department of Microbiology, Division of Chemistry, Gdańsk University of Technology, Gdańsk, Poland. abrilld@yahoo.com
Wianecka
Magdalena
M
Dabrowski
Sławomir
S
Mladenovska
Zuzana
Z
Kur
Józef
J
Ahring
Birgitte K
BK
D054458:Amplified Fragment Length Polymorphism Analysis / Q000379:methods*; D001105:Archaea / Q000235:genetics* / Q000302:isolation & purification; D001483:Base Sequence; D016172:DNA Fingerprinting; D015252:Deoxyribonucleases, Type II Site-Specific / Q000378:metabolism; D004587:Electrophoresis, Agar Gel; D004926:Escherichia coli / Q000235:genetics* / Q000302:isolation & purification; D005658:Fungi / Q000235:genetics* / Q000302:isolation & purification; D005838:Genotype; D006801:Humans; D008969:Molecular Sequence Data; D000091402:Prohibitins; D012336:RNA, Ribosomal, 16S / Q000235:genetics
C000717331:PHB2 protein, human; D000091402:Prohibitins; D012336:RNA, Ribosomal, 16S; D015252:Deoxyribonucleases, Type II Site-Specific